BALTIMORE – emocha Mobile Health is so confident its technology can help transform medication oversight for tuberculosis patients that it’s looking to apply it to different diseases like Hepatitis C, congestive heart failure and hemophilia.
That product, miDOT, is a mobile app that allows tuberculosis patients to film video of themselves taking their medication. The video is sent to a doctor or nurse for review.
“We’ll be looking to expand laterally across diseases and vertically across different markets to really move our product forward,” said Sebastian Seiguer, Mobile Health CEO and co-founder of emocha.
Traditionally, part of the treatment for tuberculosis is direct observation of the patient taking their medication. That can mean a big expense for healthcare providers that usually have to send a nurse or other worker to observe patients taking their weekly medication dose.
It can also mean danger for the patient, who could develop resistance to the medication if they fail to take it properly.
“We set out to find a way to replicate the direct observation piece at a fraction of the cost,” said Seiguer.
emocha built its product from the get-go to include other diseases. Seiguer said the software already has built-in reminders and an ability to document in-home visits by health care workers, but more work needs to be done.
“You can’t take away patient support so we need to build in elements that really support the patient,” he said. “You can’t just give them a technology and walk away.”
Part of that support will be integration with electronic health records so the visiting health care worker can see the patient’s health data and history in an easy-to-read, understandable way.
“They’ll be able to see the video and the patient’s data right away and understand it,” Seiguer said. “They will also be able to have a clue about who they are treating.”
In August, emocha contracted with three California counties that have some of the country’s highest concentrations of latent tuberculosis. This month, the company launched a full implementation of miDOT for Heptatis C patients at academic medical centers in seven cities.